Mahmoud Zaki El-Readi, Majed Abdurhman Abdulkarim, Ahmed A H Abdellatif, Mohamed E Elzubeir, Bassem Refaat, Mohammad Althubiti, Riyad Adnan Almaimani, Mohammed Hasan Mukhtar, Issa Saad Al-Moraya, Safaa Yehia Eid
Background Therapeutic resistance fails cancer treatment. Drug-nanoparticle combinations overcome resistance. Sanguinarine-conjugated nanoparticles may boost sanguinarine's anticancer effects. Methods : Sanguinarine, HPMC-NPs, and doxorubicin were tested on Adriamycin-resistant MCF-7/ADR breast cancer cells, parent-sensitive MCF-7, and MCR-5 normal cells (DX). Results : Regular distribution, 156 nm diameter, <1 μm average size, 100% intensity-SN is therapeutic. Furthermore, the obtained NPs showed PDI = 0...
January 5, 2024: Drug Development and Industrial Pharmacy